Impact of OROS® Controlled-release Delivery on Pharmacokinetics of Oxybutynin at Different Dosages: Severity-dependent Treatment of Overactive Bladder
Preik M1, Albrecht D2, O'Connel M2, Hampel C3, Anderson R4 1. Medical&Scientific Affairs,Janssen-Cilag GmbH, Germany, 2. Dep. of Clinical Development, ALZA Corporation, USA, 3. Dep. of Urology, Johannes-Gutenberg University Mainz, Germany, 4. Dep. of Urology, Stanford University, USA
|
|
Abstract 273
|
|
|
Non Discussion Posters:
Scientific Non Discussion Poster Session 19
|
|
|